{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:31:30Z","timestamp":1747193490707,"version":"3.40.5"},"reference-count":31,"publisher":"S. Karger AG","issue":"12","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Capecitabine is frequently used alone or combined with other chemotherapy agents for the treatment of metastatic breast cancer in relapsed patients. &lt;b&gt;&lt;i&gt;Objective:&lt;\/i&gt;&lt;\/b&gt; The objective of this meta-analysis is to evaluate the effectiveness and safety of capecitabine monotherapy versus combination in the treatment of metastatic breast cancer patients pretreated with anthracycline and taxane. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Eligible randomized controlled trials examining the efficacy and safety of capecitabine alone compared to capecitabine combination were systematically searched. Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and grades 3\u20134 drug-related adverse events were the outcomes assessed. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; A total of 6,714 patients of 9 trials were involved in the pooled analysis. Our findings demonstrated that capecitabine combination is significantly superior to capecitabine monotherapy in improving PFS (hazard ratio [HR] 1.32, 95% CI 1.13\u20131.54, &lt;i&gt;p&lt;\/i&gt; &amp;#x3c; 0.0001) and ORR (risk ratio [RR] 0.67, 95% CI 0.54\u20130.83, &lt;i&gt;p&lt;\/i&gt; &amp;#x3c; 0.001), but it was insignificant in OS (HR 1.09, 95% CI 0.98\u20131.22, &lt;i&gt;p&lt;\/i&gt; = 0.12). On the other hand, the incidence of non-hematological adverse events such as hand-foot syndrome and diarrhea was lower in capecitabine combination compared to capecitabine monotherapy. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; Capecitabine-based combination chemotherapy showed superiority over capecitabine monotherapy in terms of PFS and ORR, with no significant difference in OS. Non-hematological adverse effects such as hand-foot syndrome were fewer with a combination regimen. However, hematological adverse events were fewer with capecitabine monotherapy regimen. <\/jats:p>","DOI":"10.1159\/000510356","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T21:00:27Z","timestamp":1600462827000},"page":"694-702","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis"],"prefix":"10.1159","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2936-8178","authenticated-orcid":false,"given":"Louai","family":"Alsaloumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaima","family":"Shawagfeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdikarim","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilgen","family":"Basgut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq633"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2018.03.002"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.002"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy192"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.7479"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8485"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5460"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4137\/BCBCR.S32783"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.187384"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2006.n.002"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2010.02.007"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.002"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-011-1091-0"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.4244"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.13"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3892\/or.7.5.945"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2017.05.006"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064320"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0181"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2011.00945.x"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1251-y"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.098"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2013.07.006"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-016-0717-0"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30088-8"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy063"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2344"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03159.x"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2564-x"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.3.2.137"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2174\/157339406777934717"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/510356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/510356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:55:22Z","timestamp":1745423722000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000510356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,3]]},"published-print":{"date-parts":[[2021,1,6]]}},"URL":"https:\/\/doi.org\/10.1159\/000510356","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.12973100","asserted-by":"subject"}]},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"type":"print","value":"2296-5270"},{"type":"electronic","value":"2296-5262"}],"subject":[],"published":{"date-parts":[[2020]]}}}